Benzingaยท2025-09-10 18:55Group 1 - Bank of America (BofA) downgraded Acadia Healthcare Inc from Buy to Neutral and lowered the price forecast from $27 to $25 due to anticipated headwinds from Medicaid state-directed payment program cuts in 2028 and beyond [1] - Acadia's same-store volumes have decelerated to low single digits, impacted by legal issues at some locations and reduced inpatient admissions due to payor pressure [3] - Acadia Healthcare reported second-quarter adjusted earnings of 83 cents per share, exceeding the consensus estimate of 68 cents, with sales increasing 9.2% year over year to $869.23 million, also surpassing the consensus of $840.02 million [4] Group 2 - Analyst Joanna Gajuk expects volume growth to improve as new bed capacity increases, with Acadia expanding beds by 12% in 2024 and an additional 8% planned for 2025 [4] - Acadia Healthcare has revised its fiscal 2025 adjusted earnings per share guidance down from $2.50-$2.80 to $2.45-$2.65, compared to the consensus of $2.67 [5] - The company narrowed its sales guidance for fiscal 2025 from $3.3 billion-$3.4 billion to $3.3 billion-$3.35 billion, against a consensus of $3.334 billion [5]